How do we communicate risk to providers who are prescribing to pregnant and lactating women?
Assessing changes to prescription drug labeling for pregnant and lactating women
Challenge
The U.S. Food and Drug Administration (FDA) is revising the way that risk information relating to prescribing to pregnant and lactating women is presented in prescription drug labeling. Risks and benefits must be communicated to prescribing health care professionals in a clear and efficient way.
Solution
Westat conducted focus groups with health care providers to gather feedback on proposed changes to prescription drug labeling for pregnant and lactating women.
Virtual focus groups were conducted, allowing us to gather feedback across the country during a challenging time for health care providers.
Results
FDA has been using the results of the focus groups to improve risk messaging for health care providers making decisions about prescribing to pregnant and lactating women.
The project serves as a model for health care provider feedback in developing risk messaging in prescription labeling.
-
Perspective
Westat Experts Present at AAPOR 2025May 2025
Westat’s public opinion and survey methodology experts are heading to the 80th Annual American Association for Public Opinion Research (AAPOR) Conference, in St. Louis, MO,…
-
Expert Interview
Why Are People Reluctant to Share Health App Data?May 2025
In an age where smart watches track our heart rate, apps detect our sleep patterns, and digital platforms monitor the calories we burn, the potential…
-
Expert Interview
Fine-Tuning LLMs to Improve Adverse Drug Event Detection and ReportingApril 2025
The expedient, accurate detection of the severity of adverse drug events (ADEs) remains a serious challenge. Despite technological advancements, data-driven models often fail to precisely…
